Drugs / EFINEPTAKIN ALFA
EFINEPTAKIN ALFA
also known as
Efineptakina alfa · Efineptakine alfa · Hyleukin · NT-I7 · Recombinant human IL-7-hyFc · Recombinant human il-7-hyfc (nt-i7)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04054752 | May → Nov 2023 | breast carcinoma, colorectal adenocarcinoma, urinary bladder carcinoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EFINEPTAKIN ALFA | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594590 ↗ |
| Known as | Efineptakina alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594590 ↗ |
| Known as | Efineptakine alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594590 ↗ |
| Known as | Hyleukin | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594590 ↗ |
| Known as | NT-I7 | “Recombinant human IL-7-hyFc (NT-I7)” NCT04054752 ↗ |
| Known as | Recombinant human IL-7-hyFc | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04054752 ↗ |
| Known as | Recombinant human il-7-hyfc (nt-i7) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594590 ↗ |
| Modality | Protein / enzyme biologic | “a long acting IL-7 cytokine” NCT04054752 ↗ |
| Route | Intramuscular | “a single dose of NT-I7 will be delivered intramuscularly.” NCT04054752 ↗ |